MarketPulse

hematologic malignancies

5 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

TScan Therapeutics Posts $28.7M Q1 Loss as Pipeline Advances Toward Phase 3

TScan Therapeutics reports $28.7M Q1 loss, $1.0M revenue; $128.1M cash funds operations to H2 2027 amid Phase 3 pipeline advancement.
TCRXclinical developmentPhase 3 trial
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Kyowa Kirin, Kura Oncology Launch Japanese Phase 2 Trial for FDA-Approved Ziftomenib

Kyowa Kirin and Kura Oncology begin Japanese Phase 2 registrational trial for ziftomenib in relapsed/refractory NPM1-mutated AML, following FDA approval.
KURAPhase 2 clinical trialhematologic malignancies
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

TScan Therapeutics Advances TCR Cell Therapy Pipeline With FDA Clearance, Conference Participation

TScan Therapeutics secures FDA clearance for two IND applications and completes Phase 1 trial enrollment using commercial-scale manufacturing, advancing its TCR cell therapy pipeline.
TCRXclinical-stage biotechsolid tumors
The Motley FoolThe Motley Fool··Motley Fool Transcribing

Curis Posts Surprise Profit on Erivedge Sale, Pivots to Lymphoma Pipeline

$CRIS reports $19.4M Q4 earnings from one-time Erivedge sale; refocuses on PCNSL and CLL studies with $20.2M PIPE funding.
CRISearningsclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Na

TScan Advances Allogeneic Cell Therapy Pipeline With FDA IND Clearances and Trial Enrollment Milestones

TScan completes Phase 1 trial enrollment and receives FDA clearance for two allogeneic cell therapy candidates, advancing its pipeline toward pivotal studies in 2026.
TCRXclinical trialTCR-T therapy